FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease

Status Completed

Clinical Trial Summary

FGF-23 is a newly described protein that is an important regulator of phosphorus in the body. This protein increases in people with kidney disease and people who need dialysis have very high levels of FGF-23 in the blood. However, although some studies have indicated that FGF-23 levels go up with increased intake of phosphorus, no one knows if FGF-23 levels can be lowered in patients with kidney disease by preventing them from absorbing phosphorus from food. This study is designed to see what happens to levels of FGF-23 in the blood when patients with chronic kidney disease take medications to prevent phosphorus absorption. Since high levels of FGF-23 have been linked with increased rates of death in patients with advanced kidney disease, controlling the levels may, in the future, be a way to decrease heart disease in patients with kidney disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00999037
Study type	Interventional
Source	University of California, Los Angeles
Contact
Status	Completed
Phase	N/A
Start date	October 2009
Completion date	June 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02549417` - Phase 3 Study of KHK7580	Phase 3
Completed	`NCT02549404` - Phase 3 Study of KHK7580	Phase 3
Completed	`NCT02549391` - Phase 3 Study of KHK7580	Phase 2/Phase 3
Not yet recruiting	`NCT02536287` - Comparison of Total Parathyroidectomy With and Without Autotransplantation	Phase 3
Active, not recruiting	`NCT03023748` - Intravenous Paricalcitol in Chronic Hemodialysis Patients	Phase 4
Withdrawn	`NCT01426724` - Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease	N/A
Completed	`NCT01101113` - Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level	Phase 4
Completed	`NCT01220050` - Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism	Phase 2
Completed	`NCT00537979` - Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis	Phase 4
Completed	`NCT00431496` - A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD)	Phase 4
Completed	`NCT00379899` - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis	Phase 4
Completed	`NCT00073710` - Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium	Phase 4
Completed	`NCT00117052` - SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism	Phase 3
Completed	`NCT03626948` - SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis	Phase 3
Completed	`NCT01382212` - A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis	Phase 3
Completed	`NCT01219855` - Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)	Phase 2/Phase 3
Completed	`NCT01224782` - Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)	N/A
Completed	`NCT00990704` - Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism	Phase 2
Completed	`NCT00742716` - Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease	Phase 2
Recruiting	`NCT06126016` - A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.